Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone + N-acetylcysteine to prevent post-embolization syndrome after TACE in hepatocellular carcinoma
TCTR20220412008Phase 3Completed
- Sponsor
- Navamindradhiraj University Research Fund
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexamethasone, acetylcysteine in hepatocellular carcinoma (HCC), sponsored by Navamindradhiraj University Research Fund. Started Apr 2021; status: completed.
02
Drugs
dexamethasoneacetylcysteine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20220412008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220412008.